PCRX Q3 2023 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$164M-2.1% YoY

Gross Profit

$124M75.8% margin

Operating Income

$18M10.8% margin

Net Income

$11M6.6% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

-3.3%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$41M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$703M

Stockholders' Equity

$832M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$167M	-2.1%
Gross Profit	$124M	$117M	+6.3%
Operating Income	$18M	$21M	-16.8%
Net Income	$11M	-$693,000	+1666.8%

Revenue Segments

Product

$164M51%

EXPAREL/bupivacaine liposome injectable suspension

$129M40%

ZILRETTA

$29M9%

Bupivacaine Liposome Injectable Suspension

$858,0000%